Novartis plans to divest its Indian eyecare portfolio to JB Chemicals, adding to the list of MNCs reducing exposure to the Indian market. The move aligns with Novartis' strategy to capitalize on ophthalmic therapy while offering JB Chemicals entry into a growing business segment. Global Big Pharma has been divesting branded generics to Indian companies, while Indian players are diversifying from the US generics market. The deal is expected to be announced soon. The demand for eyecare is increasing due to the ageing population and greater access, driven by the use of tablets and mobile devices.
from Business News: Latest News on Business, Stock Markets, Financial News, India Business & World Business News https://ift.tt/NXHFfhB
Subscribe to:
Post Comments (Atom)
Dow soars over 1,300 pts, Sensex 900 pts
Indian markets surged on Tuesday, with the Sensex closing above 80,000 points, fueled by a global rally following Donald Trump's victory...
-
A woman, in her early 20s, was stabbed to death by a man in southeast Delhi's Bhogal area on Friday evening, following which the accused...
-
Collecting Lego — yes, the plastic toys made of interlocking bricks that become cars and castles and robots —returned more than large stocks...
-
The Delhi High Court on Thursday dismissed the pleas of TTV Dhinakaran and VK Sasikala challenging the Election Commission's order grant...
No comments:
Post a Comment